Arkolith/Insider Trading/CYCC/Form 4

Lazar David E.

Interim CEO, 10% OwnerCyclacel Pharmaceuticals, Inc. (CYCC) · full profile →Form 4 · filed Feb 28, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$5.8M
Net Open-Market Flow
-$5.8M
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 26, 2025Sell(S)194.6M$0.03$5.8M0
Feb 26, 2025Option exercise(M)2.6M——2.6M
Feb 26, 2025Option exercise(M)192.0M——194.6M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 26, 2025Option exercise(M)1.0M——0
Feb 26, 2025Option exercise(M)1.7M——355K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000921895-25-000651) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Cyclacel Pharmaceuticals, Inc.

Build

Ask your agent about CYCC insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0000921895-25-000651"
Ask your agent
Use Arkolith to summarize insider buying and selling at Cyclacel Pharmaceuticals, Inc.
over the last 90 days and cite the filings.